Eating a handful of nuts could reduce your cancer risk Just a handful of cashews could cut your risk for heart disease, cancer and premature death.
EU clears Bristol-Myers immunotherapy drug for blood cancer Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.
In a test, cancer hospital customizes diet to help patients A leading cancer hospital is tackling a big problem that keeps many patients from healing—loss of appetite.
AstraZeneca pill slashes lung cancer progression in study AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial, lifting prospects for a drug that is key to the company's ambitious long-term sales goals.
Smokeless tobacco might be far less common among big league newcomers That visible circle in the back pockets of big leaguers — typically a sure sign of smokeless tobacco — might be far less common next season.
Texas releases abortion booklet citing refuted cancer links A Texas state agency has released a new edition of a booklet for women considering an abortion that suggests there may be a link between terminating pregnancies and increased risks of breast cancer and depression.
Cancer drugs may remain approved despite lack of benefit In the United States, cancer drugs are sometimes approved through sped-up processes - and they often stay approved even if later studies show them to be inferior to other options or even worse than doing nothing, a new study found.
Glowing molecules could reveal skin cancer, without a biopsy If you want to get a mole checked to see if it's cancerous, it usually involves getting a bit of your skin sliced off and sent to a lab, in a process called a biopsy.
Novartis says 82 percent of leukemia patients in remission after CAR-T An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.
